Table 4 Commonly used cell lines for GIST research in literatures
From: Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
Cell line | Mutation | KIT expression | Imatinib sensitivity | Source | Ref |
|---|---|---|---|---|---|
Ba/F3 | Engineered to express c-Kit or PDGFRA mutants | NA | NA | Murine pro-B cell line | |
GIST882 | KIT Ex.13: K642E missense point mutation (Homo) | Positive | Sensitive | TKI-naïve metastatic human GISTs | [280] |
GIST-T1 | KIT Ex.11: in-frame deletion of 57 bp (V570-Y578) (Heter) | Positive | Sensitive | Untreated metastatic plural tumor of gastric GIST | [281] |
GIST544 | KIT Ex.9: AY503-504ins mutation | Negative | Unclear | Short-term culture from a GIST | [282] |
GIST430 | KIT Ex.11: in-frame deletion (V560-L576) (Heter) KIT Ex.13: V654A missense point mutation (Heter) | Positive | Resistant | GISTs developed resistance to imatinib therapy after initial response to imatinib therapy | |
GIST48 | KIT Ex.11: V560D missense point mutation (Homo) KIT Ex.17: D820A missense point mutation (Heter) | Positive | Resistant | GISTs developed resistance to imatinib therapy after initial response to imatinib therapy | |
GIST GDG1 | Unclear | Positive | Resistant | GIST patient progressed during imatinib treatment | |
GIST62 | KIT Ex.11: in-frame deletion (MYEVQWK552-558 T) (Heter) | Negative | Resistant | Untreated KIT-positive GIST | [284] |
GIST-DR | No Kit gene mutation | Positive | Sensitive | Rat GIST induced by duodenal reflux | [265] |
GIST522 | KIT Ex.11: in-frame deletion (EVQWK554-558) (Heter) | Negative | Resistant | Imatinib-resistant, progressing GIST | [287] |
GIST-H1 | Unclear | Positive | Unclear | Unclear | [288] |
GIST-PSW | KIT Ex.11: K558_G565delinsR mutation | Positive | Sensitive | GIST patients radiologically progressing under imatinib | [289] |
GIST-BOE | KIT Ex.9: A502_Y503dup | Positive | Resistant | GIST patients radiologically progressing under imatinib | [290] |
GIST5 | KIT Ex.11: mutations | Negative | Unclear | Established from imatinib- treated GISTs | [291] |
GIST474 | KIT Ex.11: mutations | Negative | Unclear | Established from imatinib- treated GISTs | [291] |
GIST867 | Unclear | Unclear | Resistant | Intestinal GISTs treated with imatinib | [292] |
S2 cells | KIT Ex.11: V558Δ mutation (Heter) | Negative | Resistant | KitV558Δ/+ mouse GIST tumor | [116] |
GK1C | KIT Ex.11: in-frame deletion (550–558) | Positive | Sensitive | High metastatic risk GISTs | [293] |
GK3C | KIT Ex.11: in-frame deletion (591–592) | Positive | Sensitive | High metastatic risk GISTs | [293] |
HG129 | KIT Ex.11: 45 bp insertion between F591-592G | Positive | Sensitive | Untreated primary gastric GIST | [294] |
GIST226 | KIT Ex.11: in-frame deletion (P551-W557) (Homo) KIT Ex.17: Y823D point mutation (Homo) | Negative | Resistant | Unclear | [295] |
HG209 | KIT Ex.11: in-frame deletion (YIDPTQL 570–576) KIT Ex.17: D816H point mutation | Negative | Resistant | imatinib- and sunitinib-resistant peritoneal metastasis | [296] |
GIST-5R | Δ560 − 578/T670I | Positive | Resistant | Unclear | [297] |
GIST54 | Unclear | Negative | Resistant | Unclear | [298] |